PDA

View Full Version : 'replicel news release'



Artista
05-23-2013, 09:41 AM
Dr. Jerry Shapiro to Present RepliCel Data to European Academy of Dermatology and Venereology in Poland.

VANCOUVER, BC - May 23, 2013 - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF) (CDNX: RP) reports that one of its founders, Dr. Jerry Shapiro, MD, FRCPC, will be presenting RepliCel's Phase I safety data and the concept of using dermal sheath cup cells for hair growth at the 10th European Academy of Dermatology and Venereology (EADV) Spring Symposium in Cracow, Poland on May 25th at 12:00 PM local time. The focus of the conference is on the "burden of skin disease".

"The RepliCel data from its RCH-01 Phase I trial treating pattern baldness is very promising," commented Dr. Shapiro, one of RepliCel's founders. "The trial provided the Company with safety and early efficacy data supporting a progression to the next phase. RepliCel's proposed Phase II dose-ranging study is designed to confirm the efficacy of injections of RCH-01 in over 100 male participants and will provide over 288 data points as compared to 16 in the Phase I trial. The Phase II trial should determine what the optimum dose is to promote hair growth," concluded Dr. Shapiro.

About Dr. Jerry Shapiro

Dr. Shapiro is one of the most experienced hair dermatologists in the world and has specialized in hair disorders for the past 22 years. He holds dual academic appointments as Clinical Professor and Adjunct Professor at both the University of British Columbia and New York University School of Medicine. Dr. Shapiro is the founder of the first comprehensive integrated medical and surgical hair clinic in the world. He has trained over thirty international hair fellows from four continents. He has published over 100 peer-reviewed papers, 15 book chapters and two books. He has lectured internationally on hair related topics on 173 occasions on 6 continents.

UK_
05-23-2013, 09:58 AM
Better than Aderans who seem dead?

Only thing is, Dr David Hall said a year ago could look at 2015 release but their timeline states that in 2015 Phase 2 will only be finished - so once again (as has been happening consistently for the past 30 years), the "5 year" mark is being pushed back.

Now we're looking at 2017, I remember 3 years ago it was the same story with 2015, no doubt in 24 months the buzz-year on release will be '2020' and so on and so on.

JulioGP
05-23-2013, 11:11 AM
Better than Aderans who seem dead?

Only thing is, Dr David Hall said a year ago could look at 2015 release but their timeline states that in 2015 Phase 2 will only be finished - so once again (as has been happening consistently for the past 30 years), the "5 year" mark is being pushed back.

Now we're looking at 2017, I remember 3 years ago it was the same story with 2015, no doubt in 24 months the buzz-year on release will be '2020' and so on and so on.

Do not be so pessimistic about that. Not everything happens in time we would like. These schedules are altered, as it is not child's play and are being invested millions of dollars that can not be thrown away.

It is normal to happen this kind of delay particularly when working with clinical trials. See AIDS or cancer occurs in the same away despite the focus here is the recovery of hair instead of diseases that lead to death.

Thinning87
05-23-2013, 01:35 PM
is phase 2 confirmed for the second part of 2013, or are they still looking for investors to sponsor it?

UK_
05-24-2013, 01:16 AM
is phase 2 confirmed for the second part of 2013, or are they still looking for investors to sponsor it?

Phase 2 is confirmed, btw, for those that know about Replicel, they wont suffer in finding investors lol.

Arashi
05-24-2013, 01:19 PM
is phase 2 confirmed for the second part of 2013, or are they still looking for investors to sponsor it?

They just closed a private placement for CAD$509,502 last month. They'll probably do the same again in the (near) future.

Thinning87
05-24-2013, 01:36 PM
They just closed a private placement for CAD$509,502 last month. They'll probably do the same again in the (near) future.

and that is enough to go into phase 2? That's nothing!

Arashi
05-24-2013, 01:48 PM
and that is enough to go into phase 2? That's nothing!

That's why I added "They'll probably do the same again in the (near) future". But do keep in mind phase II is generally way cheaper than phase III.

eqvist
05-24-2013, 01:54 PM
That's why I added "They'll probably do the same again in the (near) future". But do keep in mind phase II is generally way cheaper than phase III.

Okey that i didnīt know. Why is phase 2 cheaper?

garethbale
05-24-2013, 02:15 PM
Okey that i didn´t know. Why is phase 2 cheaper?

More number of test subjects is the main reason I think, Phase 2 is usually a few dozen subjects, phase 3 a few hundred

Thinning87
05-24-2013, 02:17 PM
That's why I added "They'll probably do the same again in the (near) future". But do keep in mind phase II is generally way cheaper than phase III.

if it's just 20-30 subjects the amount raised should about do it shouldn't it?

Arashi
05-24-2013, 02:55 PM
More number of test subjects is the main reason I think, Phase 2 is usually a few dozen subjects, phase 3 a few hundred

Exactly.

Arashi
05-24-2013, 02:56 PM
if it's just 20-30 subjects the amount raised should about do it shouldn't it?

Maybe. But they were totally out of cash to begin with (http://finance.yahoo.com/q/ks?s=REPCF+Key+Statistics ) and have a huge cash burn rate, so I'm assuming they're going to try another placement this year.

Thinning87
05-24-2013, 03:00 PM
I kind of want to buy 5-10K worth of stock to gamble on this

yagazooci
05-26-2013, 02:20 PM
I think Replicel are poised to do very well in this race. Looks as though they have sold a licence to someone to use their technology. At least that is what the graphics seem to show on their Product Pipeline for the hair technology, on the Replicel site. If that is the case then they will not have generated revenue?? Something up there by the look of it.

http://www.replicel.com/wp-content/uploads/RCH-01-hair.png

We'll see.